Efficacy and safety of zenagamtide s.c. once weekly compared to placebo in participants with type 2 diabetes and chronic kidney disease inadequately controlled on once daily basal insulin alone or in combination with metformin, SGLT2i, or both (AMBITION 2)

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2026-525471-13-00

Enrollment

Registered

2026-10-27

Start date

Unknown

Completion date

Unknown

Last updated

2026-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Participants with type 2 diabetes and chronic kidney disease

Brief summary

Change in glycated haemoglobin (HbA1c)

Detailed description

Relative change in body weight, Change in waist circumference, Change in triglycerides, Change in high-sensitivity C-reactive protein (hsCRP), Change in Non-high-density lipoprotein (Non-HDL) cholesterol, Change in systolic blood pressure, "Change in 7-point self-measured plasma glucose (SMPG) profiles: Mean postprandial increment (over all meals)"

Interventions

DRUGzenagamtide B 10176

DRUGNNC0487-0111 B 10144

DRUGNNC0487-0111 B 10145

DRUGPlacebo (Zenagamtide)

DRUGNNC0487-0111 B 10143

DRUGNNC0487-0111 B 10142

DRUGNNC0487-0111 B 10141

DRUGNNC0487-0111 B 10146

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change in glycated haemoglobin (HbA1c)	—

Secondary

Measure	Time frame
Relative change in body weight, Change in waist circumference, Change in triglycerides, Change in high-sensitivity C-reactive protein (hsCRP), Change in Non-high-density lipoprotein (Non-HDL) cholesterol, Change in systolic blood pressure, "Change in 7-point self-measured plasma glucose (SMPG) profiles: Mean postprandial increment (over all meals)"	—

Outcome results

None listed

Source: EU CTIS · Data processed: Oct 29, 2026